Macrophage immunometabolic reprogramming in inflammatory repair failure in osteonecrosis of the femoral head Authors: Yan Wang, LuLu Zhang, XueZhi Liu, Dong Wang, JianXiong Ma Published: 2026 ABSTRACT AbstractThe classical “vascular occlusion” model does not fully account for osteonecrosis of the femoral head (ONFH). Femoral head collapse may progress despite restored perfusion, and ischemia alone cannot adequately explain steroid-associated ONFH. We propose that ONFH involves disruption of bone-vascular-immune homeostasis, with macrophage immunometabolic reprogramming in response to hypoxic and lipotoxic stress acting as a potential driver of inflammatory repair failure. Among the metabolic mechanisms implicated in ONFH, the strongest disease-specific evidence supports roles for hypoxia, oxidative stress, disordered lipid metabolism, macrophage imbalance, and ferroptosis-associated injury. By contrast, macrophage-specific glycolytic reprogramming, remodeling of the tricarboxylic acid (TCA) cycle, epigenetic fixation, osteomac dysfunction, and cuproptosis remain less well established. Regulated cell death pathways, particularly ferroptosis and pyroptosis, may exacerbate local tissue injury by releasing damage-associated molecular patterns (DAMPs) and inflammatory mediators that disrupt type H vessel-osteogenesis coupling and shift repair toward fibrosis. Establishing causal relationships rather than correlative associations will require lineage-tracing experiments, spatial validation, metabolic flux analyses, and genetic loss-of-function studies in ONFH models.The translational potential of this articleViewing ONFH as an immunometabolic disorder identifies experimentally tractable targets beyond conventional anti-inflammatory strategies, including SLC7A11/GPX4-dependent ferroptosis defense, NLRP3 inflammasome signaling, and HIF-1α-associated macrophage metabolic adaptation. Extracellular vesicle- or biomaterial-based delivery systems designed for prolonged local retention should currently be considered experimental platforms for assessing lesion-specific target engagement in early-stage ONFH. Their clinical relevance must be established through ONFH-specific studies evaluating efficacy, safety, biodistribution, manufacturability, and long-term structural outcomes.Keywords: Osteonecrosis of the femoral head (ONFH), Osteoimmunology, Immunometabolism, Ferroptosis, Type H vessel, Macrophages Introduction Osteonecrosis of the femoral head (ONFH) is a debilitating skeletal disorder characterized by progressive loss of subchondral bone integrity and eventual collapse of the femoral head [1,2]. It predominantly affects young and middle-aged adults, and advanced disease often requires total hip arthroplasty, which is associated with a substantial risk of revision surgery and a considerable socioeconomic burden [[1], [2], [3], [4]]. Clinical staging and treatment selection should be guided by the 2019 Association Research Circulation Osseous (ARCO) staging system and the clinical guideline for adult ONFH [5,6]. ONFH arises from heterogeneous etiological insults, including traumatic vascular disruption, prolonged corticosteroid exposure, excessive alcohol consumption, and idiopathic or multifactorial nontraumatic causes [2,3,7]. Despite their differing origins, these insults converge on the femoral head, an anatomically confined and mechanically vulnerable site. Within this environment, ischemia, osteocyte death, lipid metabolic disturbances, microvascular dysfunction, and impaired bone remodeling interact to progressively reduce the opportunity for successful joint-preserving intervention [[1], [2], [3],[7], [8], [9]]. The pathogenesis of ONFH has traditionally been interpreted primarily in terms of vascular insufficiency and impaired perfusion [2,8,10,11]. This model remains central to explaining ischemic initiation and provides the rationale for core decompression, vascularized bone grafting, and other joint-preserving procedures. However, clinical and experimental observations indicate that restoration of perfusion does not invariably result in durable biological repair. Even after macrovascular patency has been restored, cellular repair at the boundary of necrotic tissue may remain incomplete, and remodeling may favor fibrosis, sclerosis, or mechanically inadequate cancellous bone rather than structurally competent regeneration [8,[10], [11], [12]]. Ischemia may therefore represent a major initiating event without being the sole determinant of disease progression. Repair failure may also depend on whether the local microenvironment retains sufficient immune, vascular, metabolic, and osteogenic capacity to support coordinated tissue regeneration. This microenvironmental perspective is particularly relevant to steroid-associated ONFH. Although glucocorticoids (GCs) exert potent systemic immunosuppressive effects, corticosteroid exposure is also associated with adipogenic differentiation of bone marrow stromal cells, lipid accumulation, oxidative stress, osteocyte and endothelial injury, and defective local tissue repair [3,7,9,13]. Together, these changes may establish a hypoxic and lipotoxic niche within the femoral head in which macrophage-mediated clearance, resolution of inflammation, endothelial stability, and osteogenic repair become uncoupled. Advances in single-cell and spatial transcriptomics, together with findings from preclinical ONFH models and human histopathological studies, now provide opportunities to characterize this lesion-specific microenvironment in greater detail [12,14,15]. Current evidence supports macrophage accumulation and phenotypic imbalance in ONFH lesions and suggests interactions among monocyte–macrophage populations, endothelial cells, osteoblast-lineage cells, neutrophil-associated inflammatory pathways, and regulated cell death programs [[13], [14], [15], [16], [17], [18]]. However, the amount and directness of ONFH-specific evidence vary considerably across proposed mechanisms. These include macrophage-specific glycolytic reprogramming, trained-immunity-like epigenetic fixation, S100A8/A9-associated inflammatory macrophage states, osteomac dysfunction, type H vessel remodeling, endothelial-to-mesenchymal transition, neutrophil extracellular trap (NET)-associated microthrombosis, and cuproptosis. This review is a critical narrative review rather than a systematic review (Fig. 1). We integrate evidence from human ONFH studies, preclinical ONFH models, single-cell and spatial omics analyses, skeletal repair biology, vascular biology, and models of sterile inflammatory disease to construct an evidence-stratified bone-vascular-immune framework for ONFH pathogenesis. To avoid presenting correlative omics findings or mechanisms extrapolated from related diseases as established causal processes, we classify the mechanisms discussed into three broad categories: those supported by ONFH-specific evidence, those inferred indirectly from related musculoskeletal, vascular, or sterile inflammatory conditions, and hypothesis-generating mechanisms that require direct validation in ONFH. This evidence hierarchy informs the interpretation of pathogenic mechanisms and translational recommendations throughout the manuscript (Table 1 and Supplementary Table S1). Etiology-dependent lesion microenvironments within the bone-vascular-immune framework of ONFH. Glucocorticoid exposure, alcohol use, trauma, and other insults converge on a hostile femoral-head microenvironment characterized by hypoxia, lipotoxicity, oxidative stress, and DAMP release. These stressors may remodel macrophage fate and metabolism, amplify regulated cell death and inflammatory signaling, impair endothelial and type H vessel function, and ultimately compromise angiogenic–osteogenic coupling. The schematic summarizes proposed interactions among bone, vascular, and innate immune components within the ONFH lesion and should be interpreted as a conceptual framework rather than a fixed temporal sequence. Table 1Evidence-stratified mechanisms implicated in the bone–vascular–immune framework of ONFH.Table 1MechanismCurrent evidence statusCausal confidenceKey validation neededFerroptosisRelatively stronger ONFH-related evidenceModerateCell-type-specific SLC7A11/GPX4 perturbationPyroptosisEmerging ONFH-related evidenceModerate-limitedNLRP3/caspase-1/GSDMD inhibition or deletionHIF-1α glycolytic switchBiologically plausible with partial ONFH supportLimited-moderateMyeloid-specific HIF-1α intervention and metabolic flux analysisNET-associated microthrombosisEmerging but spatially incomplete evidenceLimited-moderatePAD4/DNase intervention with vascular endpointsOsteomac dysfunctionStrong bone-biology rationale, limited ONFH-specific validationLimitedSpatial lineage tracing and rescue experimentsCuproptosisMainly extrapolated from mitochondrial copper biologyHypothesis-generatingCopper burden and FDX1/DLAT/lipoylation validationNote: Detailed experimental strategies, readouts, and stage-dependent endpoints are provided in Supplementary Table S1. Evidence-stratified mechanisms implicated in the bone–vascular–immune framework of ONFH. Note: Detailed experimental strategies, readouts, and stage-dependent endpoints are provided in Supplementary Table S1. Previous studies have examined immune microenvironment remodeling, macrophage polarization, extracellular vesicle-based therapies, and biomaterial-assisted regeneration in ONFH [19,20]. Accordingly, this review does not present microenvironment-targeted therapy as an entirely novel concept. Instead, it integrates these approaches into a stage-specific, evidence-stratified framework centered on macrophage immunometabolism. Within this framework, the bone compartment encompasses osteocytes, osteoblast-lineage cells, osteoclasts, osteomacs, and trabecular integrity; the vascular compartment comprises endothelial cells, the microcirculation, type H vessels, endothelial-to-mesenchymal transition, and immunothrombosis; and the immune compartment includes primarily macrophages, neutrophils, NET-associated responses, and DAMP-driven sterile inflammation within ONFH lesions. Bone repair failure, vascular dysfunction, and sterile inflammation are therefore considered interdependent processes, although the strength of evidence for causal involvement varies across mechanisms and disease stages. Future joint-preserving strategies should consequently extend beyond structural support or angiogenic stimulation alone to incorporate rigorously validated immunometabolic interventions. Relevant translational endpoints should include resolution of inflammation, endothelial heterogeneity, type H vessel–osteogenesis coupling, trabecular preservation, biomechanical competence, and long-term maintenance of femoral head integrity. Macrophage heterogeneity in ONFH: single-cell and spatial evidence Current ONFH-specific evidence supports macrophage accumulation and phenotypic imbalance within necrotic and reparative regions, but the precise identities of disease-associated macrophage states remain incompletely defined. We therefore consider macrophage-state remodeling to be supported in ONFH, while regarding specific subset identities, including S100A8/A9-associated inflammatory myeloid or macrophage states, as hypothesis-generating until they are confirmed through spatial and functional analyses. In bone immunology, the M1/M2 dichotomy has long provided a conventional framework for macrophage classification. However, this binary model is inherently reductive and may not adequately represent the biological complexity of macrophage behavior in ONFH [21]. Single-cell RNA sequencing (scRNA-seq) provides a more nuanced view. Rather than forming discrete and stable categories, macrophages within necrotic lesions appear to occupy a dynamic transcriptional continuum [14,22]. The ischemic and lipotoxic microenvironment imposes context-dependent functional demands on both tissue-resident macrophages and newly recruited monocyte-derived cells within the necrotic niche. Available transcriptomic studies of ONFH indicate enrichment of inflammatory, hypoxia-adaptive, angiogenic, and matrix-remodeling programs in the diseased femoral head. However, direct single-cell evidence for macrophage-specific programs involving IL1B, TNF, CD36, LPL, MMP9, HIF1A, and VEGFA remains limited [[22], [23], [24], [25]]. This transcriptional heterogeneity may reflect the combined effects of impaired intraosseous perfusion, systemic and local lipid metabolic dysfunction, heme released during hemolysis, and persistent damage-associated molecular pattern (DAMP) signaling. Perilesional cells that remain metabolically active despite severe ischemic stress may continue to release DAMPs into the surrounding microenvironment [14,22]. Collectively, these stressors may drive macrophages toward diverse functional states that cannot be adequately distinguished using conventional surface markers such as CD86 and CD206. Elucidating the pathogenesis of ONFH requires analytical approaches that extend beyond conventional cell counting and jointly assess cellular identity, spatial context, and metabolic state [14,21,22,26]. Rigorous characterization of the macrophage microenvironment should integrate, at minimum, two established dimensions: transcriptional phenotype and anatomical localization [14,22,26]. Metabolic profiling represents an additional but still largely unexplored dimension. Such a multilayered approach is needed to distinguish the interconnected contributions of local inflammation, microvascular insufficiency, and dysregulated bone remodeling and to clarify the sequence of events that may ultimately lead to femoral head collapse (Fig. 2A) [14,21,22]. Single-cell transcriptomic analyses combined with histological validation further suggest that the abundance of innate immune effector populations varies across radiographically defined disease stages, although these stage-associated changes require longitudinal confirmation [14,21,22]. Macrophage-state remodeling and zonal lesion organization in ONFH. The ONFH lesion may contain a continuum from resident or reparative bone-associated macrophage states to inflammatory and fibrogenic programs under hypoxic, oxidative, and cytokine-rich conditions. A putative S100A8/A9-associated inflammatory myeloid/macrophage state may contribute to neutrophil recruitment, NET formation, microthrombosis, and impaired perfusion. Spatially, the lesion can be organized into necrotic core, inflammatory interface, reactive sclerotic rim, fibrotic containment wall, and adjacent reparative compartment, supporting zone-specific rather than uniform immunomodulation. To avoid replacing the oversimplified M1/M2 framework with another set of rigid classifications, we define the macrophage states discussed in this review operationally rather than as fixed or mutually exclusive lineages. Here, S100A8/A9-associated inflammatory macrophages refer to a putative proinflammatory myeloid/macrophage program characterized by alarmin signaling, cytokine amplification, neutrophil recruitment, and matrix-remodeling activity. Although this state may share features with classically activated M1-like macrophages, it should not be regarded as equivalent to the M1 phenotype. Studies of osteoarthritis and related sterile inflammatory conditions have identified S100A8/A9-associated macrophage programs that contribute to joint pathology [27,28]. In ONFH, available single-cell data suggest activation of S100A8/A9-related inflammatory pathways [29]. We therefore consider this program a candidate inflammatory state that may mediate macrophage–neutrophil crosstalk and NET-associated microvascular injury within the necrotic niche (Fig. 2B) [17,21]. Osteomacs are defined as bone-lining, tissue-resident macrophage-like cells located along osteoblast-lined and endosteal surfaces, where they support osteoblast survival, matrix mineralization, and bone repair. In ONFH, osteomac dysfunction should be viewed as a testable contributor to impaired osteogenesis rather than as a fixed M2-like phenotype. Expanded operational definitions of other macrophage states, including recruited inflammatory monocyte-derived macrophages and reparative or resolution-associated macrophages, are provided in Supplementary Table S2. Osteomac dysfunction represents another potential determinant of failed bone repair that has received relatively limited attention. These bone-lining resident macrophages normally reside in close apposition to the endosteal surface, where they maintain osteoblast viability and preserve the integrity of the bone-forming layer [30]. Loss or functional impairment of osteomacs would deprive the local environment of an important pro-osteogenic signal and may thereby compromise repair at the necrotic boundary [21,30]. When the resident macrophage niche is disrupted, repair sites may become progressively infiltrated by recruited monocyte-derived macrophages that engage in aberrant paracrine signaling with mesenchymal fibroblast-like cells. Through profibrotic mediators such as TGF-β and PDGF, this crosstalk may redirect stromal cell fate from osteoblastic mineralization toward pathological fibrogenesis [31]. The resulting “fibrotic switch” is proposed to produce dense but mechanically inferior scar tissue that lacks the trabecular architecture required for load-bearing function [31]. Defining the spatiotemporal dynamics of macrophage–fibroblast interactions, and determining whether these interactions differ between GC- and alcohol-induced ONFH, will be necessary to explain why repair may culminate in nonfunctional fibrous tissue rather than functional bone regeneration [12,31]. Single-cell sequencing characterizes the cellular and secretory landscape of ONFH tissue, whereas spatial transcriptomics reveals the anatomical distribution of these transcriptional differences [12,26]. Based on histopathological descriptions of necrotic, reparative, and sclerotic regions in ONFH, together with emerging spatial omics studies of bone, the lesion can be conceptualized as a zonally organized microenvironment rather than a homogeneous tissue compartment (Fig. 2C) [12,26]. At its center is an acellular necrotic zone characterized histologically by marrow necrosis, osteocyte death with empty lacunae, and saponification of free fatty acids (FFAs) within the extracellular matrix. Experimental and clinical studies also implicate oxidative stress and lipid peroxidation products, including MDA and 4-HNE, in the progression of osteonecrosis [32]. Surrounding the necrotic core is a metabolically active inflammatory zone populated by macrophages. ONFH transcriptomic data suggest that these cells express matrix-remodeling, inflammatory, and hypoxia-adaptive programs involving mediators such as MMP-9, caspase-1, and HIF-1α [12,14,21,22]. Under homeostatic conditions, such programs would facilitate the clearance of necrotic matrix as a prerequisite for subsequent bone repair. In the ONFH microenvironment, however, persistent inflammatory signaling and metabolic stress may shift macrophages toward pathological states characterized by excessive matrix degradation [12,21]. This imbalance between tissue resorption and formation may be further aggravated in the adjacent peripheral trabecular zone, where osteoclast-rich regions within the macrophage-dominated inflammatory front progressively erode the remaining trabeculae. This process may create focal concentrations of mechanical stress, promote subchondral microfractures, and ultimately contribute to structural collapse [12,21]. Spatially resolved analyses therefore support a model in which femoral head collapse results not only from passive ischemic injury but also from active immune-mediated weakening of the osseous structure [12,21]. Beyond the inflammatory zone, a reactive sclerotic ring develops that is composed predominantly of fibrotic tissue and alternatively activated macrophages [21]. This spatial organization may represent a maladaptive containment response. When necrotic debris cannot be effectively cleared, the surrounding tissue may form a calcified barrier that separates the lipid-rich necrotic core from viable marrow. This process may perform a fibrocalcific containment function analogous, although not necessarily identical in cellular composition, to an encapsulation response. Although such containment may restrict lesion expansion in the short term, its structural consequences may be detrimental. The sclerotic rim forms a relatively impermeable physical barrier that may obstruct residual periosteal blood flow, attenuate reparative signals from adjacent healthy marrow, and prevent bone marrow mesenchymal stem cells from entering the regenerative niche [12,21]. Mechanically, fluid accumulation within the isolated region may promote cyst formation and exacerbate stress shielding, thereby redistributing compressive loads toward the sclerotic core and potentially accelerating degeneration of the internal trabecular network. This immune-mediated compartmentalization identifies several candidate therapeutic objectives, including resolving immunosuppression, restoring microenvironmental permeability, and facilitating osteoprogenitor access to the regenerative niche [12,21]. Immunometabolic reprogramming: ONFH evidence and extrapolated mechanisms Current ONFH-specific evidence most strongly supports the presence of hypoxia, oxidative stress, and lipid metabolic disturbances within femoral head lesions, whereas direct evidence for macrophage-specific glycolytic and mitochondrial reprogramming remains limited. Accordingly, HIF-1α-associated glycolytic reprogramming and tricarboxylic acid (TCA) cycle remodeling are discussed here as plausible upstream mechanisms that require validation through cell-type-specific metabolic flux analyses and loss-of-function studies. Macrophage effector functions in ONFH are closely linked to immunometabolic status. Metabolic pathways serve not only as sources of ATP but also as upstream regulators that may shape the transcriptional landscape and functional state of activated macrophages [18,25,33]. Following pathological injury to the femoral head, macrophages may undergo metabolic reprogramming in response to a microenvironment characterized by hypoxia, necrotic bone-derived DAMP/TLR4 signaling, impaired perfusion, and steroid- and lipid-associated stress. This response may share features with the Warburg-like inflammatory phenotype, including HIF-1α stabilization and enhanced aerobic glycolysis, although its upstream drivers differ from those that operate in tumor metabolism [23,25,34,35]. HIF-1α-dependent transcription may increase the expression of glycolytic regulators such as HK2 and glucose transporters such as GLUT1/SLC2A1, thereby enhancing glucose uptake (Fig. 3A) to support the increased biosynthetic demands of inflammatory cytokine and lipid mediator production [34,35]. Immunometabolic modules that may sustain macrophage activation in ONFH. Hypoxia-driven HIF-1α activation may promote glycolysis, lactate accumulation, and inflammatory persistence. Glycolytic diversion into the PPP and disrupted TCA-cycle checkpoints may enhance ROS generation and immunomodulatory metabolite signaling. Lipid overload may induce foam-cell-like remodeling, ER stress, lipid peroxidation, and inflammasome activation. Mitochondrial injury may further activate mtROS, cGAS–STING signaling, NF-κB activity, and metabolic–epigenetic memory. This hyperglycolytic shift may have two pathological consequences. First, lactate accumulation in poorly perfused ONFH lesions may promote local acidosis and inflammatory pain signaling, although this association is extrapolated from studies of acidosis-induced osteoclast activation and bone pain. Second, diversion of glycolytic intermediates into the pentose phosphate pathway may increase NADPH availability and support NOX2-dependent reactive oxygen species (ROS) generation [35]. In addition to glycolytic dysregulation, macrophages in ONFH may undergo mitochondrial metabolic reprogramming rather than simple mitochondrial failure [36,37]. Based on established models of inflammatory macrophage activation, we propose that disruption of the TCA cycle may contribute to ONFH pathophysiology [[36], [37], [38]]. If a comparable metabolic discontinuity occurs in ONFH, it may promote the accumulation of immunoregulatory metabolites such as succinate and itaconate. Rather than functioning as a continuous oxidative cycle, the TCA cycle in ONFH macrophages may become disrupted at the citrate/isocitrate-processing and succinate dehydrogenase (SDH) nodes, producing a state of “metabolic discontinuity” (Fig. 3B) [[36], [37], [38]]. Altered SDH activity may reshape intracellular succinate pools. In parallel, induction of IRG1/ACOD1 converts cis-aconitate into itaconate, representing a distinct but temporally overlapping metabolic response [37,38]. Succinate may be particularly relevant to ONFH pathogenesis. When it accumulates and is redistributed from the mitochondrial matrix to the cytosol or extracellular space, succinate can function as a signaling metabolite that inhibits prolyl hydroxylase domain proteins (PHDs). This effect may sustain HIF-1α stability even after oxygen availability has been restored, thereby establishing a “pseudohypoxic” feedback loop that perpetuates sterile inflammation [35,39]. Extracellular succinate may also activate SUCNR1/GPR91 through autocrine and paracrine signaling, potentially amplifying context-dependent macrophage activation and IL-1β-associated inflammatory cascades [39]. In steroid-induced ONFH, the endogenous immunoregulatory activity of itaconate may be inadequate or dysregulated, although current evidence does not demonstrate direct GC-mediated suppression of ACOD1/IRG1 in ONFH macrophages [38,[40], [41], [42], [43]]. Under physiological conditions or during inflammatory resolution, ACOD1-derived itaconate suppresses inflammation through several mechanisms, including inhibition of SDH and alkylation of KEAP1, which releases and activates the Nrf2 antioxidant pathway [38,40,41]. Recent evidence further indicates that GCs can reprogram macrophage mitochondrial metabolism to maintain itaconate production, whereas activation of the ACOD1-itaconate pathway has been shown to attenuate steroid-associated osteonecrosis in mice [42,43]. Collectively, these findings support a model in which TCA cycle remodeling shifts mitochondrial function away from energy production and toward immunometabolic signaling. Under these conditions, mitochondria may act as pathological signaling centers that sustain proinflammatory transcriptional programs within the femoral head microenvironment [[36], [37], [38], [39], [40], [41], [42], [43]]. Lipid handling represents a second, closely interconnected axis of immunometabolic stress in ONFH macrophages. Although glycolysis is a fundamental adaptation to oxygen deprivation, its dysregulation intersects with the lipid metabolic abnormalities that characterize steroid-induced ONFH. GC exposure disrupts systemic lipid metabolism and simultaneously promotes the accumulation and hypertrophy of bone marrow adipocytes, thereby increasing FFA concentrations within the femoral head microenvironment [9,44]. This lipid-rich environment imposes a substantial metabolic burden on infiltrating macrophages, which must process an excessive influx of FFAs [18,44]. Under physiological conditions, alternatively activated macrophages associated with inflammatory resolution rely predominantly on mitochondrial fatty acid β-oxidation (FAO) to meet their bioenergetic requirements. This metabolic program supports sustained anti-inflammatory and tissue-reparative capacity [45]. In the ONFH microenvironment, however, lipid homeostasis may be disrupted at both the uptake and oxidation stages. Consistent with their effects in other metabolic and inflammatory settings, GCs and local inflammatory mediators may act synergistically to increase the expression or activity of the scavenger receptor CD36 in ONFH macrophages, thereby promoting excessive uptake of extracellular lipids (Fig. 3C) [46]. Simultaneously, hypoxia-driven HIF-1α activation and steroid-associated metabolic stress may restrict CPT1A-dependent mitochondrial FAO, the rate-limiting pathway governing the transport of long-chain fatty acids into mitochondria [44,47,48]. This combined increase in lipid uptake and reduction in lipid oxidation may create a metabolic trap in which unoxidized lipids accumulate within the cytoplasm as triglycerides and cholesteryl esters [47,48]. Functionally competent macrophages may consequently be transformed into lipid-laden, poorly phagocytic foam cells. This transition may have two pathological consequences: interstitial crowding that disrupts tissue architecture and bioenergetic insufficiency that impairs complete M2-like polarization [18,47,48]. Reduced FAO may also decrease mitochondrial acetyl-CoA production and the downstream nucleocytosolic acetyl-CoA pool required for histone acetylation, thereby limiting transcriptional activation of repair-associated macrophage programs [49]. This metabolic–epigenetic constraint may contribute to the persistence of a proinflammatory and functionally impaired macrophage state, although the causal importance of this mechanism is likely to vary according to biological context [49]. Current ONFH-specific evidence strongly supports the involvement of lipid overload, oxidative stress, lipid peroxidation, and ferroptosis-associated injury. By contrast, the macrophage-specific sequence linking CD36-mediated lipid uptake, impaired fatty acid oxidation, mitochondrial dysfunction, and persistent inflammation remains supported largely by indirect evidence and requires experimental validation in ONFH models. Within this framework, intracellular lipid accumulation may do more than displace cellular components; it may initiate a cascade of lipotoxic reactions that disrupt cellular homeostasis [50,51]. Increased glycolytic flux and NOX-dependent activity may generate excessive ROS, promoting the peroxidation of stored polyunsaturated fatty acids (PUFAs) and the formation of highly electrophilic aldehydes, including 4-hydroxy-2-nonenal (4-HNE) [50,51]. These reactive products can form covalent adducts with cellular proteins and membrane phospholipids, thereby compromising the structural and functional integrity of organelles such as the endoplasmic reticulum (ER) and mitochondria [51,52]. The accumulation of misfolded proteins and lipid adducts within the ER lumen may induce sustained ER stress. Although the initial unfolded protein response (UPR) is adaptive, persistent lipotoxic stress in the ONFH microenvironment may shift this response toward a maladaptive state in which CHOP-dependent transcription promotes apoptosis [52]. Concurrently, lipotoxic intermediates and membrane disruption, as demonstrated in other models of metabolic stress, may provide potent “signal 2” stimuli for NLRP3 inflammasome assembly, leading to caspase-1-dependent maturation and release of the pro-osteoclastogenic cytokine IL-1β [53]. This pathway also generates mature IL-18, whose effects on bone remodeling may be either inhibitory or stimulatory depending on the local cytokine milieu and T-cell involvement. Its specific contribution to ONFH pathogenesis remains to be determined experimentally [53]. Lipid overload may therefore provide a mechanistic link between metabolic dysregulation and structural bone loss by sustaining sterile inflammation and creating a local cytokine environment that suppresses osteoblast differentiation independently of pathogen exposure [25,53]. Under conditions of chronic substrate excess, macrophages may themselves develop progressive metabolic dysfunction and shift from coordinating tissue repair to promoting tissue destruction. This transition is consistent with the clinical observation that withdrawal of corticosteroids alone is often insufficient to reverse established ONFH and with experimental evidence that depletion of M1-like macrophages can delay the progression of GC-associated ONFH [25,33]. ONFH oxidative-stress studies provide partial support for mitochondrial dysfunction, whereas its proposed links to macrophage metabolic memory and epigenetic fixation remain hypothesis-generating. Mitochondria occupy a central regulatory position within this immunometabolic network and may function not only as targets of cellular stress but also as active transducers of inflammatory signaling [54,55]. In the ONFH microenvironment, macrophage mitochondria may undergo both morphological and bioenergetic remodeling, potentially as a consequence of dysregulated mitochondrial dynamics [[54], [55], [56]]. Persistent danger signals released from necrotic tissue, together with hypoxia, may activate the mitochondrial fission GTPase Drp1 through phosphorylation. Subsequent translocation of Drp1 to the mitochondrial membrane may promote excessive fragmentation of the mitochondrial network, producing dispersed, punctate organelles [56,57]. These fragmented mitochondria may exhibit impaired electron transport chain efficiency and loss of membrane potential, thereby becoming major sources of intracellular ROS [56,57]. Mitochondria-derived ROS may exert two complementary pathological effects. First, they may directly induce oxidative injury in neighboring osteoblasts. Second, they may promote oxidation-dependent activation of IκB kinase, thereby sustaining NF-κB signaling and trapping macrophages in a self-reinforcing cycle of ROS production, inflammation, and persistent cytokine release [33,56,57]. When mitochondrial injury exceeds a critical threshold, mitochondrial DNA (mtDNA) may enter the cytosol through several mechanisms, including opening of the mitochondrial permeability transition pore (mPTP), mitochondrial outer membrane permeabilization (MOMP), and oligomerization of voltage-dependent anion channels (VDACs) [58,59]. Cytosolic mtDNA retains features of its bacterial ancestry, including unmethylated CpG motifs, and can activate the cGAS-STING–IRF3 pathway, potentially inducing a type I interferon response. This sequence provides a plausible molecular basis for sterile inflammation in the ONFH niche (Fig. 3D) [58,59]. Mitochondrial dysfunction may also reduce the production of α-ketoglutarate, an essential cofactor for ten-eleven translocation (TET) DNA demethylases and Jumonji C (JmjC) domain-containing histone demethylases [55,60]. Reduced α-ketoglutarate availability may impair TET- and JmjC-dependent demethylation, potentially promoting promoter hypermethylation or repressive chromatin states at anti-inflammatory gene loci [60,61]. Such epigenetic changes could establish a proinflammatory form of metabolic memory that persists after withdrawal of the initial corticosteroid stimulus and renders the pathogenic macrophage phenotype resistant to reversal [33,60,61]. Regulated cell death and microvascular injury in ONFH During the progression of ONFH, regulated cell death (RCD) is not merely a terminal consequence of tissue injury. Several forms of RCD may also exert immunomodulatory effects that amplify local sterile inflammation, impair tissue repair, and establish a self-reinforcing cycle of tissue destruction [[62], [63], [64]]. Among the pathways discussed below, ferroptosis is supported by comparatively strong ONFH-related evidence, whereas evidence for pyroptosis is emerging but remains incomplete. Cuproptosis is largely hypothetical in ONFH and is inferred primarily from studies of mitochondrial copper biology. Ferroptosis is particularly consistent with the ischemic and lipotoxic microenvironment of ONFH, which is characterized by impaired blood supply, hypoxia, and GC-induced disruption of lipid metabolism. It may therefore represent a major candidate mechanism driving the transition from structurally stable disease to irreversible femoral head collapse [16,[64], [65], [66], [67], [68]]. Ferroptosis is an iron-dependent form of regulated necrotic cell death caused by the accumulation of lipid peroxides under conditions of oxidative imbalance and intracellular iron overload [62,63,69]. The femoral head microvasculature is highly susceptible to ischemic injury because perfusion depends on a relatively limited collateral network. Repetitive mechanical loading and hemodynamic fluctuations may further predispose the region to microvascular damage and focal hemorrhagic stress [64]. Under these conditions, macrophage-mediated processing of hemoglobin and heme, together with heme oxygenase-1 (HO-1)-dependent heme catabolism, may expand the cytosolic labile iron pool (LIP). This process could increase the availability of ferrous iron (Fe2+) for Fenton reactions and hydroxyl radical generation [62,63,69]. Concomitantly, GC-induced systemic dyslipidemia and local lipid metabolic disturbances may promote the accumulation of ferroptosis-sensitive phospholipids containing polyunsaturated fatty acids (PUFAs). In particular, phosphatidylethanolamines containing arachidonic acid (AA) or adrenic acid (AdA) are considered preferential substrates for oxidative phospholipid damage during ferroptosis [65]. Under physiological conditions, lipid peroxides are detoxified through the system Xc−-glutathione (GSH)-glutathione peroxidase 4 (GPX4) axis. The heterodimeric cystine/glutamate antiporter, composed of SLC7A11 and SLC3A2, imports extracellular cystine to sustain GSH synthesis, whereas GPX4 uses GSH as a cofactor to reduce toxic lipid hydroperoxides to their corresponding alcohols [62,63,69]. However, concurrent hypoxia, oxidative stress, and GC exposure may compromise this antioxidant system through p53-associated repression of SLC7A11, depletion of intracellular GSH, and reduced GPX4-dependent detoxification of lipid peroxides, thereby leaving PUFA-rich membranes vulnerable to oxidative damage [16,[66], [67], [68]]. Ferrous iron may then catalyze Fenton-type reactions that propagate lipid ROS generation, disrupt membrane integrity, and trigger ferroptotic cell death (Fig. 4A) [62,63,69]. Unlike apoptosis, ferroptosis is increasingly recognized as a lytic and proinflammatory form of regulated necrosis. Ferroptotic cells may undergo plasma membrane rupture and release DAMPs, including HMGB1 and other cytosolic danger signals. These molecules may activate pattern-recognition receptor pathways in neighboring immune cells and promote sterile necroinflammation [69]. Pharmacological radical-trapping agents, including Ferrostatin-1 and Liproxstatin-1, provide proof of concept that ferroptotic lipid peroxidation can be interrupted. In ONFH-relevant experimental systems, Ferrostatin-1 reverses dexamethasone-induced ferroptotic changes. Other ferroptosis-targeted interventions, including GDF15-mediated melatonin signaling, regulation of the miR-370-3p–TLR4/SLC7A11/GPX4 axis, and SIRT3-dependent coupling between mitophagy and ferroptosis, have also ameliorated GC-associated ONFH phenotypes in preclinical models [16,66,68,70]. Together with clinical evidence associating reduced GPX4 and SLC7A11 expression with the severity of nontraumatic ONFH, these findings support ferroptosis as a potentially actionable therapeutic pathway rather than merely a passive endpoint of tissue injury [67]. Regulated cell death, immunothrombosis, endothelial-to-mesenchymal transition (EndoMT), and type H vessel disruption in ONFH. Ferroptosis, pyroptosis, NET-driven immunothrombosis, endothelial dysfunction, EndoMT, and type H vessel loss may interact to amplify vascular niche failure and inflammatory repair impairment. Ferroptotic lipid peroxidation and pyroptotic IL-1β/IL-18 release may reinforce sterile inflammation, whereas NET-associated microthrombosis and EndoMT may aggravate local hypoxia and impair angiogenic–osteogenic coupling. This schematic is conceptual and does not imply quantitative pathway dominance. Mechanistically distinct from ferroptosis, pyroptosis is a lytic form of programmed cell death driven by inflammasome activation. Its defining feature is the coupling of cell death to the unconventional release of mature proinflammatory cytokines, primarily IL-1β and IL-18, through GSDMD pores, thereby potentially amplifying local inflammation [71,72]. The canonical “two-signal” model of NLRP3 inflammasome activation has been extensively characterized in infectious, sterile inflammatory, and autoinflammatory diseases [73,74]. In this model, “signal 1” may arise from NF-κB-mediated transcriptional priming induced by the initial ischemic or corticosteroid-related insult, whereas “signal 2” may be provided by the abundant DAMPs, oxidative stress, and lipid peroxidation-derived danger signals within the necrotic niche [[73], [74], [75]]. Following NLRP3 activation, the adaptor protein ASC assembles a supramolecular complex that recruits pro-caspase-1 and promotes its proximity-induced autocatalytic activation [73,74]. Active caspase-1 then cleaves gasdermin D (GSDMD), releasing its cytotoxic N-terminal fragment (GSDMD-N), which oligomerizes within the plasma membrane to form large transmembrane pores [72,76]. These pores disrupt ionic gradients, induce osmotic water influx, and ultimately cause cellular swelling and membrane rupture (Fig. 4B). They also provide conduits for the rapid, unconventional release of mature IL-1β and IL-18, further intensifying the local inflammatory milieu [71,72,76]. This pathway may contribute to the persistently elevated IL-1β signaling observed in ONFH tissues. However, cytokine alterations in synovial fluid may also reflect secondary inflammation associated with synovial and cartilage degeneration rather than intraosseous pyroptosis alone [77,78]. IL-1β promotes osteoclastogenesis, increases RANKL expression in osteoblasts and stromal cells, and simultaneously inhibits osteoblast maturation. These effects may establish a pathological inflammation–resorption cycle that progressively compromises femoral head integrity and increases susceptibility to subchondral collapse [53]. While mechanistically plausible, the direct contribution of pyroptosis to ONFH requires further experimental confirmation [77,78]. Cuproptosis provides a hypothesis-generating perspective on immunometabolic dysregulation in ONFH. Unlike ferroptosis, which is driven by iron-dependent lipid peroxidation, and pyroptosis, which is mediated by inflammasome–gasdermin signaling, cuproptosis is linked to mitochondrial oxidative metabolism. Excess copper binds to lipoylated proteins of the TCA cycle, particularly DLAT, causing protein aggregation, destabilization of iron-sulfur clusters, and proteotoxic stress [79,80]. This metabolic dependence may have immunological consequences because reparative or resolution-associated macrophage states that rely more heavily on oxidative phosphorylation could be particularly susceptible to copper-induced proteotoxic injury [81,82]. Altered copper homeostasis within the ONFH microenvironment could therefore impair reparative macrophage function and perpetuate inflammatory imbalance [13,18,23,33,80]. Copper chelation remains an experimental strategy supported primarily by indirect evidence from other inflammatory disease models and should be evaluated cautiously in ONFH-specific systems [79,80]. In addition to affecting macrophage viability and inflammatory persistence, regulated cell death pathways may converge on the vascular niche, thereby linking immune-cell injury to endothelial dysfunction and impaired osteogenic support. ONFH-specific evidence supports endothelial injury, microvascular dysfunction, and disruption of angiogenesis–osteogenesis coupling, whereas EndoMT and type H vessel remodeling remain candidate mechanisms within the vascular niche. Ferroptotic injury may increase lipid peroxidation products, redox imbalance, and DAMP release, while inflammasome-associated pyroptosis may amplify IL-1β and IL-18 secretion and intensify local sterile inflammation. Collectively, these signals may compromise endothelial survival, barrier integrity, perivascular support, and endothelial–osteogenic communication, thereby reducing the capacity to maintain or regenerate CD31+Emcn+ type H vessels. Conversely, the loss or dysfunction of type H vessels may exacerbate local hypoxia, nutrient deprivation, mitochondrial stress, and oxidative injury, further increasing the susceptibility of bone and vascular cells to regulated cell death. Regulated cell death and type H vessel disruption may therefore establish a bidirectional pathological loop connecting immune activation, vascular failure, and defective osteogenesis in ONFH. Because direct ONFH-specific evidence for several components of this proposed loop remains limited, future studies should integrate cell death markers with spatially resolved vascular, endothelial, and osteogenic assessments rather than infer vascular rescue from isolated molecular changes. Building on this regulated cell death (RCD)-vascular niche framework, the inflammatory and oxidative consequences of cell death may progressively damage the microvascular architecture of the femoral head. The resulting endothelial dysfunction and microcirculatory failure may not only perpetuate ischemic injury but also preferentially impair specialized vascular subtypes required for osteogenesis-coupled repair [[83], [84], [85], [86], [87]]. Type H vessels, defined by high co-expression of CD31 and endomucin (Emcn), normally coordinate angiogenic and osteogenic activity. Within the ONFH microenvironment, however, proinflammatory mediators released by inflammatory macrophages and pyroptotic cells may induce transcriptional and functional abnormalities in type H endothelial cells. These mediators may suppress the flow-responsive Notch signaling pathway that maintains the type H vascular phenotype and reduce endothelial secretion of osteogenic angiocrine factors, including PDGF-B and CXCL12, thereby uncoupling vascular perfusion from osteogenic support [18,78,[85], [86], [87]]. Microvascular integrity may be further compromised by immune-mediated thrombosis. Chemotactic alarmins, including S100A8/A9 complexes released from necrotic and inflamed tissues, may recruit and activate neutrophils at sites of injury. Activated neutrophils may then release NETs, which are chromatin-based structures decorated with cytotoxic proteases, citrullinated histones, myeloperoxidase, and other oxidative enzymes [88]. In cardiovascular and systemic inflammatory models, NETs act as intravascular scaffolds that promote platelet adhesion and activation, erythrocyte entrapment, coagulation factor activation, and thrombus stabilization [88]. Given the marked microcirculatory impairment observed in ONFH, a similar mechanism may operate within the sterile inflammatory environment of the femoral head. NET-forming neutrophils have been detected in small vessels surrounding the femoral head in idiopathic ONFH, and recent experimental evidence indicates that modulation of NET formation can improve ONFH-associated endothelial phenotypic transition and vascular dysfunction [17,89]. Localized NETosis may therefore induce focal occlusion of the residual microcirculation and provide a mechanistic link between sterile inflammation and persistent perfusion failure in ONFH (Fig. 4C). The combined effects of type H vessel depletion and NET-mediated immunothrombosis may help explain why microcirculatory perfusion and osteogenic repair remain impaired despite macrovascular or surgical revascularization [17,84,87,89]. The chronic inflammatory milieu generated by these pathological processes may also favor EndoMT, a form of phenotypic reprogramming increasingly implicated in microvascular rarefaction and endothelial dysfunction in steroid-associated ONFH (Fig. 4D) [17,[90], [91], [92]]. Sustained exposure to TGF-β, together with persistent oxidative stress, may suppress endothelial lineage markers such as CD31 and VE-cadherin/CDH5 while inducing mesenchymal programs characterized by the expression of α-SMA/ACTA2, COL1A1, and S100A4/FSP1 [[90], [91], [92], [93], [94]]. EndoMT involves more than a change in marker expression. Disruption of endothelial junctions may impair barrier integrity and increase vascular permeability, whereas EndoMT-associated vascular remodeling and fibrogenic activation may promote luminal narrowing, perivascular matrix deposition, and the progressive loss of functional microvessels [90,94,95]. Functionally reprogrammed endothelial cells may lose their angiogenic and tissue-supportive properties and acquire a matrix-producing phenotype, thereby contributing to interstitial fibrosis and disrupting the microvascular conduits required for tissue repair [17,[90], [91], [92],94,95]. At the structural level, these changes are consistent with capillary rarefaction and partial luminal obliteration, accompanied by the replacement of reparative space with fibrotic tissue that is unfavorable for osteogenic ingrowth [12,90,95]. The reactive sclerotic zone observed in ONFH specimens may therefore arise, at least in part, from fibrotic remodeling around the necrotic region. However, direct lineage-tracing evidence demonstrating that this tissue originates from EndoMT-derived endothelial cells in human ONFH remains unavailable [12,90]. Collectively, these mechanisms suggest that progressive disruption of osteoangiogenic coupling may involve three interconnected processes: (i) RCD-induced necroinflammation that sustains a cytokine-rich local inflammatory milieu; (ii) NET-mediated microvascular occlusion that interrupts residual perfusion; and (iii) EndoMT-associated microvascular dysfunction that removes the structural conduits required for repair. These self-perpetuating immune and vascular responses may progressively erode the biological framework required for tissue regeneration, promoting structural insufficiency and, without timely intervention, eventual segmental collapse [17,[88], [89], [90]]. Target validation and delivery strategies Conventional joint-preserving treatments for ONFH, including core decompression, porous tantalum implantation, vascularized or nonvascularized bone grafting, and biological scaffolds such as decellularized bone matrix, primarily provide mechanical support, preserve reparative space, and facilitate osteoconduction. These interventions remain essential for restoring local architecture, particularly in mechanically unstable lesions. However, they do not directly correct the immune, vascular, and metabolic abnormalities that sustain ONFH progression [96,97]. This limitation is especially relevant to steroid-associated ONFH, in which osteoimmune imbalance, macrophage metabolic reprogramming, oxidative stress, endothelial dysfunction, mitochondrial injury, and lipid peroxidation collectively create a microenvironment that is unfavorable for durable bone regeneration (Fig. 5A) [19,21,54,75,98]. Emerging therapeutic approaches should therefore be assessed not merely as novel delivery systems but as platforms for validating and modulating disease-relevant immunometabolic targets. Within this framework, HIF-1α-associated glycolytic reprogramming, SLC7A11/GPX4-dependent ferroptosis defense, and NLRP3/GSDMD-mediated pyroptotic amplification represent three priority axes for investigation in ONFH. These targets differ substantially in the strength of their supporting evidence. Ferroptosis is supported by comparatively strong ONFH-specific experimental data, whereas HIF-1α-associated macrophage glycolytic reprogramming and NLRP3/GSDMD-mediated pyroptotic amplification remain biologically plausible but require more direct functional validation in ONFH-specific models. The therapeutic rationale, evidentiary basis, and required validation endpoints for these three axes are summarized in Fig. 5B and Table 2. Target-driven immunometabolic therapy and experimental delivery strategies for ONFH. Table 2Priority immunometabolic targets and required validation readouts in ONFH.Table 2Target axisTherapeutic rationaleTherapeutic readinessKey validation prioritySLC7A11/GPX4 ferroptosis axisLipid peroxidation and ferroptosis-associated injury are linked to oxidative damage, repair failure, and structural deterioration in ONFH.Preclinical ONFH rationale relatively strongConfirm cell-type-specific ferroptosis rescue and evaluate vascular, trabecular, and bone-repair outcomes.NLRP3/caspase-1/GSDMD pyroptosis axisPyroptotic inflammatory amplification may connect DAMP release, macrophage activation, IL-1β/IL-18 production, endothelial injury, and impaired osteogenesis.Candidate inflammatory amplification targetValidate macrophage-specific pyroptosis and test whether pathway inhibition preserves endothelial and osteogenic repair.HIF-1α–glycolysis axisHypoxia-associated metabolic stress may contribute to inflammatory macrophage persistence, impaired efferocytosis, and defective vascular–osteogenic repair.Upstream hypothesis requiring myeloid-specific validationDemonstrate macrophage-specific metabolic rewiring and test myeloid-specific HIF-1α or glycolytic perturbation in ONFH models. Priority immunometabolic targets and required validation readouts in ONFH. Three priority axes are proposed for ONFH target validation: HIF-1α–glycolysis-mediated macrophage maladaptation, SLC7A11/GPX4-dependent ferroptosis defense, and NLRP3/GSDMD-mediated pyroptotic amplification. Delivery systems, including extracellular-vesicle-based platforms, ROS-responsive carriers, and hydrogel- or scaffold-integrated local release systems, are positioned as experimental tools for lesion-localized target engagement. RNA interference or gene-editing approaches should currently be regarded as mechanistic perturbation tools rather than clinically validated ONFH therapies. The hypoxic, poorly perfused microenvironment of the necrotic femoral head may stabilize HIF-1α and induce a Warburg-like glycolytic shift in macrophages, thereby increasing inflammatory cytokine production, lactate accumulation, redox imbalance, and persistence of a proinflammatory phenotype [54,75,98]. From a therapeutic perspective, the central question is not merely whether HIF-1α is activated, but whether controlled modulation of HIF-1α activity or downstream glycolytic flux can restore the inflammation-resolving capacity of macrophages without compromising physiological hypoxia-induced angiogenesis. Future studies should therefore combine pharmacological or genetic modulation of HIF-1α with direct assessments of target engagement, including HIF-1α activity, GLUT1 and HK2 expression, glycolytic flux, lactate production, mitochondrial respiration, macrophage phenotype, efferocytic capacity, and inflammatory markers such as TNF-α, IL-1β, and NF-κB activation. These cellular readouts should be linked to tissue-level outcomes, including endothelial survival, preservation of type H vessels, osteogenic support, and type H vessel–osteogenesis coupling. Delivery systems may facilitate target validation by enabling spatially restricted modulation of HIF-1α or glycolytic regulators at the lesion interface, thereby limiting systemic toxicity and avoiding excessive suppression of adaptive responses to hypoxia. Among the regulated cell death pathways implicated in ONFH, ferroptosis is currently one of the most strongly supported therapeutic targets. Steroid exposure, lipid overload, mitochondrial dysfunction, and oxidative stress may increase lipid peroxidation and impair antioxidant defenses, thereby sensitizing osteocytes, endothelial cells, osteoblast-lineage cells, and potentially macrophages to ferroptotic injury [19,50,54,75]. The SLC7A11/GPX4 system is central to cellular defense against lipid peroxidation, and restoration of this pathway may preserve reparative cell populations and prevent the amplification of sterile inflammation. Therapeutic validation should therefore determine whether restoration of SLC7A11 or GPX4 reduces lipid ROS, malondialdehyde, 4-hydroxynonenal, ACSL4 expression, and ferroptosis-associated cell loss in ONFH models. Functional outcomes should extend beyond molecular rescue to include osteocyte and endothelial survival, trabecular preservation, osteogenesis, vascular integrity, and the mechanical strength of the femoral head. Ferroptosis-targeted therapy should therefore be considered effective only when biochemical suppression of lipid peroxidation translates into improved osteovascular repair and structural preservation. Stimulus-responsive biomaterials and nanocarriers may be particularly suitable for ferroptosis-targeted therapy because they can be engineered to respond to the oxidative microenvironment. ROS-responsive biomaterials may enable lesion-localized cargo release while concurrently reducing excessive oxidative stress [[99], [100], [101], [102], [103]]. However, their therapeutic value should be assessed on the basis of SLC7A11/GPX4 target engagement, suppression of lipid peroxidation, preservation of reparative cells, and improvement in osteovascular repair rather than material responsiveness alone. The NLRP3 inflammasome and its downstream caspase-1/GSDMD pathway provide a plausible mechanism linking DAMP accumulation, macrophage activation, IL-1β and IL-18 release, and pyroptotic amplification of sterile inflammation in ONFH [75,98,104]. Therapeutic studies should therefore determine whether pharmacological inhibition or genetic deletion of NLRP3, caspase-1, or GSDMD reduces macrophage inflammatory activation, pyroptotic membrane rupture, DAMP release, endothelial injury, and impaired osteogenesis. Relevant readouts should include NLRP3 activation, caspase-1 cleavage, GSDMD-N formation, IL-1β and IL-18 release, DAMP production, macrophage viability, endothelial barrier function, type H vessel preservation, and bone repair outcomes. Such analyses would allow pyroptosis-targeted therapies to be evaluated as mechanism-specific interventions rather than nonspecific anti-inflammatory approaches. RNA interference, microRNA modulation, and gene-editing technologies should currently be positioned as preclinical tools for mechanistic investigation and target validation, with careful assessment of delivery efficiency, cell-type specificity, off-target effects, and incremental benefit over established joint-preserving treatments [[105], [106], [107], [108], [109], [110]]. Importantly, immunometabolic therapy should be considered a biological complement to, rather than a replacement for, current joint-preserving surgery. Procedures such as core decompression, porous tantalum implantation, vascularized or nonvascularized bone grafting, and scaffold-based reconstruction primarily provide decompression, space maintenance, structural support, osteoconduction, and partial restoration of vascular supply [1]. However, these interventions are not specifically designed to reverse the immune–metabolic, oxidative, and regulated cell death abnormalities that may impair osteovascular repair within the necrotic femoral head. The principal clinical value of target-driven immunometabolic therapy may therefore lie in improving the lesion microenvironment in which surgical reconstruction must function. In early-stage or biologically active ONFH, modulation of persistent HIF-1α-associated glycolytic reprogramming, SLC7A11/GPX4-dependent ferroptosis defense, or NLRP3/GSDMD-mediated inflammatory amplification may enhance macrophage-mediated resolution, endothelial survival, type H vessel–osteogenesis coupling, trabecular preservation, and the durability of joint-preserving procedures. Target selection should nevertheless be stratified by etiology because nontraumatic ONFH is a multifactorial disorder involving distinct combinations of vascular, metabolic, genetic, and environmental factors [2]. Steroid-induced ONFH may be particularly amenable to strategies targeting lipid peroxidation, ferroptosis, mitochondrial ROS, and macrophage metabolic exhaustion. By contrast, alcohol-induced ONFH may require greater emphasis on aberrant stromal cell differentiation, endothelial dysfunction, oxidative stress, and disordered lipid handling [1,2,14]. In trauma-induced ONFH, restoration of blood supply and mechanical stability should remain the primary therapeutic priorities because acute interruption of femoral head perfusion and subsequent ischemic structural damage are likely to predominate; immunometabolic modulation should therefore be considered a secondary adjunct [111]. Idiopathic and other nontraumatic forms may require biomarker-guided treatment selection based on the predominant immune, vascular, or metabolic abnormality [2]. These etiologic comparisons are summarized in Table 3 and Supplementary Table S3. Table 3Etiology-stratified integration of immunometabolic targets with current joint-preserving strategies in ONFH.Table 3ONFH subtypeDominant pathological pressurePriority immunometabolic targetPotential adjunct to joint-preserving surgerySteroid-induced ONFHLipotoxicity, oxidative stress, ferroptosis, macrophage metabolic exhaustionSLC7A11/GPX4, HIF-1α–glycolysis, NLRP3/caspase-1/GSDMDCore decompression combined with local ferroptosis or metabolic modulationAlcohol-induced ONFHLipid metabolic disorder, endothelial injury, stromal heterogeneityEndothelial protection, macrophage lipid handling, oxidative stress controlVascular-preserving surgery combined with endothelial or metabolic therapyTraumatic ONFHMechanical vascular disruption, ischemia–reperfusion injury, repair failureAngiogenesis, transient inflammatory control, osteomac preservationRevascularization or bone grafting combined with short-window immunomodulationIdiopathic/non-traumatic ONFHMixed immune-metabolic and microvascular factorsBiomarker-guided individualized targetingStage-adapted combined therapy based on imaging, vascular, and inflammatory status Etiology-stratified integration of immunometabolic targets with current joint-preserving strategies in ONFH. Within this clinical framework, engineered delivery systems should be viewed as enabling technologies for achieving lesion-localized target engagement rather than as stand-alone therapeutic modalities (Fig. 5C). Because ONFH lesions are deeply situated, poorly perfused, and often enclosed by a sclerotic rim, perilesional, scaffold-integrated, or intraosseous administration may offer advantages over exclusively systemic delivery. Delivery platforms should therefore be evaluated primarily according to lesion retention and penetration, cellular specificity, target engagement, immunological safety, and functional rescue in ONFH-specific models. Extracellular vesicle-based systems, ROS-responsive carriers, and scaffold-integrated local-release platforms have shown experimental potential, including an exosome-functionalized, extracellular matrix-mimicking hydrogel evaluated in GC-induced ONFH [112]. Their efficacy should be assessed using predefined assays matched to the intended therapeutic target, such as modulation of HIF-1α-associated glycolysis, restoration of SLC7A11/GPX4-dependent ferroptosis defense, or inhibition of NLRP3/caspase-1/GSDMD signaling (Table 2). These molecular effects should be linked to downstream outcomes, including cellular rescue, endothelial–osteogenic coupling, restoration of type H vessels, trabecular preservation, biomechanical competence, maintenance of femoral head integrity, and reduced risk of collapse. Delivery performance should also be evaluated in terms of release kinetics, off-target toxicity, and long-term outcomes in appropriately selected animal models (Fig. 5D). Large-animal models are particularly valuable for assessing lesion-scale delivery, mechanical loading, and structural repair, although no existing model fully recapitulates all features of human ONFH [113]. The translational value of these delivery systems therefore lies not in their technical complexity but in their ability to achieve reproducible local target engagement, acceptable safety, and additional therapeutic benefit when combined with clinically relevant joint-preserving procedures. Translational challenges and stage-gated validation roadmap Although immunomodulatory materials have the potential to improve the pathological microenvironment of ONFH, their clinical translation is constrained by disease heterogeneity, limited model fidelity, manufacturing complexity, unresolved questions regarding long-term immunological safety, and uncertain regulatory classification [114,115]. No smart material specifically designed to remodel the immune microenvironment of ONFH has entered established clinical practice. Current management remains centered on risk-factor modification, joint-preserving procedures for early-stage disease, and arthroplasty after structural failure [32,116]. Bridging this translational gap requires a stage-gated development pathway rather than the continued accumulation of isolated proof-of-concept studies. We therefore propose an operational roadmap that integrates model qualification, comparative efficacy testing, predefined safety-related go/no-go criteria, product-specific critical quality attributes (CQAs) and release standards, and clinical evaluation stratified by disease etiology and stage (Fig. 6). Stage-gated translational roadmap for immunometabolic therapy in ONFH. Candidate interventions should progress from human-relevant in vitro or ex vivo systems to small-animal ONFH models, weight-bearing large-animal models, and early clinical evaluation as adjunctive therapies. Validation should include target engagement, cell-level functional rescue, vascular and osteogenic repair, biomechanical outcomes, lesion retention, biodistribution, immune safety, manufacturing consistency, and long-term structural preservation. Clinically, such strategies are most plausibly positioned as adjuncts to established joint-preserving procedures in early-stage or biologically active ONFH. Rodent models induced by corticosteroid administration, alcohol exposure, or local physical injury remain useful for mechanistic screening. However, they do not fully reproduce the chronic disease course, immune phenotype, skeletal architecture, or progressive load-bearing collapse observed in human ONFH [19,25]. Cross-species immune markers must therefore be interpreted cautiously. For example, murine Arg-1 expression should not be used as a stand-alone surrogate for reparative macrophage function in humans. Candidate mechanisms should instead be validated in human-derived cells using broader transcriptional, metabolic, and functional readouts [117,118]. Before clinical translation, candidate interventions should progress through a staged validation sequence comprising human-relevant in vitro or ex vivo systems, small-animal ONFH models, appropriately justified weight-bearing large-animal models, and, finally, early-phase clinical evaluation as adjunctive therapy (Fig. 6A). Steroid-, alcohol-, and trauma- or ischemia-induced ONFH should be modeled separately. Animals should be stratified using an ARCO-like imaging framework and evaluated longitudinally at early, intermediate, precollapse, and postcollapse stages. Minimum outcome domains should include MRI-based assessment of perfusion and lesion characteristics; micro-CT evaluation of trabecular and subchondral architecture; histological analysis; vascular density; type H vessel markers; spatially resolved macrophage phenotypes; osteogenic activity; and the mechanical strength of the femoral head. Because the risk of collapse in humans is strongly influenced by lesion location and size, lateral pillar involvement, and regional stress distribution, biomechanical performance should be assessed alongside biological repair [[119], [120], [121]]. Candidate therapies should also be compared with clinically relevant surgery-alone and combination-treatment groups, such as core decompression alone versus core decompression combined with an immunometabolic intervention, to determine whether they provide additional benefit beyond established joint-preserving procedures. Humanized multicellular systems incorporating immune, vascular, and osteogenic components may provide a complementary layer of validation. Bone-on-a-chip, vascularized bone-marrow-on-a-chip, and induced pluripotent stem cell–derived organoid systems have already provided proof of concept in related settings, although a fully integrated ONFH-specific platform has yet to be established [[122], [123], [124]]. Safety assessment of immunomodulatory materials must extend beyond conventional short-term biocompatibility because these systems are designed to alter immune-cell behavior, signaling dynamics, and tissue remodeling rather than function as inert implants [125,126]. As outlined in Fig. 6B, delivery-system evaluation should therefore assess not only lesion penetration, retention, release kinetics, and target specificity but also off-target effects, immunological safety, and long-term toxicity. A stage-gated development program should incorporate predefined safety-related go/no-go criteria. Local treatment should be temporally limited and, where technically feasible, reversible because prolonged or excessive activation of repair-associated pathways may promote TGF-β-, PDGF-, macrophage-, and myofibroblast-mediated fibrosis without restoring mechanically competent trabecular bone [[127], [128], [129], [130], [131]]. Development should not proceed if treatment induces persistent systemic cytokine activation; sustained abnormalities in neutrophil, monocyte, T-cell, or natural killer cell profiles; prolonged systemic immunosuppression; increased susceptibility to infection; impaired biofilm clearance; delayed wound healing; or evidence of disrupted tumor immune surveillance. At the lesion level, ectopic ossification, excessive fibrosis, aberrant vascular proliferation, and suppression of physiological bone remodeling should be regarded as adverse outcomes rather than evidence of successful regeneration. Demonstration of target engagement and structural repair should therefore be accompanied by restoration of immune homeostasis after treatment withdrawal and the absence of persistent local or systemic immune dysfunction. Because universal numerical thresholds cannot be applied across products and experimental models, each development program should prospectively define the acceptable direction, magnitude, duration, reversibility, and biological significance of treatment-induced immune changes. This operational strategy should be incorporated into a broader material immunotoxicology framework that evaluates not only the intrinsic toxicity of the material but also its intended and unintended effects on immune-cell composition, immune surveillance, resistance to infection, and systemic immune function [115,127,128]. For extracellular vesicle-based products, including exosomes, translational claims should remain restrained unless product identity, purity, potency, sterility, stability, biodistribution, and batch-to-batch reproducibility have been clearly defined [[132], [133], [134], [135]]. Potency assays should be aligned with the proposed mechanism of action rather than rely on generic anti-inflammatory readouts. Depending on the intended target, these assays may assess restoration of SLC7A11/GPX4 activity, inhibition of NLRP3/caspase-1/GSDMD signaling, suppression of IL-1β release, enhancement of efferocytosis, or improvement in endothelial–osteogenic coupling [[132], [133], [134], [135]]. Potency testing should be linked to target-specific validation at the molecular, cellular, tissue, and functional or structural levels, as summarized in Fig. 6C. A product should not advance solely because it elicits a favorable biological signal in vitro. It should also demonstrate reproducible manufacturing, target-specific potency, compliance with predefined safety criteria [[132], [133], [134], [135]], adequate lesion retention, acceptable biodistribution, and functional benefit in ONFH-relevant models [136,137]. The ultimate translational objective is not generalized immune suppression but spatially and temporally controlled intervention tailored to lesion biology and etiological subtype. Region-resolved microarchitectural, histological, single-cell, and spatial transcriptomic evidence supports subdivision of the femoral head into the necrotic core, the inflammatory or reparative interface, the sclerotic barrier, and the adjacent viable bone niche [12,14,26,138]. Materials delivered to the necrotic–inflammatory interface should provide calibrated suppression of sterile inflammation while supporting the recruitment of vascular and progenitor cells. Interventions directed at the sclerotic zone should prioritize restoration of the microvasculature, remodeling of the physical barrier, and control of maladaptive bone turnover. Constructs interacting with viable bone should promote osteogenic coupling and mechanical integration [12,[138], [139], [140]]. Treatment should also be adapted to disease phase because inflammation, angiogenesis, osteogenesis, and remodeling occur in an overlapping and nonlinear sequence rather than as discrete stages. Prolonged delivery of a single immunological signal may therefore compromise subsequent phases of repair [[139], [140], [141], [142], [143]]. Programmable or microenvironment-responsive systems may be used to attenuate early inflammatory injury and subsequently support vascular and osteogenic regeneration, provided that their release kinetics and biological effects are directly validated. Etiology should also be incorporated into treatment design because steroid-, alcohol-, and trauma-associated ONFH differ in their metabolic, vascular, inflammatory, and mechanical drivers [3,138]. Candidate circulating, serum, imaging, and tissue biomarkers may ultimately facilitate patient stratification, but they should currently be regarded as investigational until prospectively validated [19,144,145]. Within this stage-gated framework, only interventions that collectively demonstrate human-relevant target engagement, additional benefit beyond established joint-preserving procedures, acceptable biomechanical performance, restoration of immune homeostasis, manufacturing consistency, compliance with product-specific critical quality attributes, and safety in appropriately staged large-animal models should advance to early clinical evaluation. Consistent with the clinical positioning summarized in Fig. 6D, initial trials should preferentially evaluate these therapies as adjuncts to established joint-preserving procedures in patients stratified by etiology and imaging findings. Longitudinal endpoints should include pharmacodynamic activity, immunological responses, imaging findings, structural outcomes, and safety. Clinical significance and translational potential: The clinical value of this framework lies in extending ONFH treatment beyond structural salvage toward stage-specific correction of the lesion microenvironment. By identifying ferroptosis, inflammasome-mediated amplification of inflammation, and macrophage metabolic maladaptation as testable therapeutic axes, this review provides a rationale for combining joint-preserving procedures with lesion-localized immunometabolic modulation. Future translational studies should prioritize ONFH-specific target engagement, safety, manufacturability, and clinically meaningful outcomes, including preservation of type H vessel–osteogenesis coupling, trabecular integrity, biomechanical competence, and long-term survival of the femoral head. Conclusion and prospects Recent research on ONFH has increasingly shifted from structural reconstruction alone toward defining the biological conditions required for sustained tissue regeneration. Trabecular disruption and subchondral collapse are established histopathological features of ONFH. However, emerging evidence suggests that clinical outcomes depend not only on mechanical stabilization but also on whether the boundary of the necrotic lesion retains the capacity to initiate and sustain reparative signaling. Conventional approaches centered primarily on revascularization or load redistribution have shown stage-dependent and often limited efficacy in achieving durable biological repair. Although vascularized grafting at an early stage can preserve femoral head integrity in selected patients, outcomes remain variable and decline markedly as the disease advances. This therapeutic gap supports an immunometabolic framework in which the ischemic and lipotoxic microenvironment is regarded not merely as a consequence of necrosis but as an active determinant of cellular fate. Within this environment, monocyte and macrophage populations may undergo substantial remodeling. Proinflammatory and chemotactic subsets may expand within necrotic regions, whereas homeostasis-supporting tissue-resident macrophages, including osteomacs, may become depleted or functionally impaired through metabolic exhaustion and regulated cell death. Macrophages may also develop increased aerobic glycolysis, impaired mitochondrial oxidative phosphorylation, and disrupted iron and lipid homeostasis. Through epigenetic reinforcement, these metabolic abnormalities may become self-sustaining and maintain macrophages in persistent proinflammatory states. Ferroptosis and pyroptosis may subsequently amplify local injury through the release of DAMPs and inflammatory mediators, thereby extending pathological signaling beyond the initial lesion. Concurrently, NET formation and immunothrombosis may impair microvascular patency and interfere with reparative remodeling. Collectively, these processes may destabilize the bone-vascular-immune network. Declining type H vessel density and progressive EndoMT may shift regenerative remodeling toward fibrosis and sclerosis, reducing trabecular mechanical competence despite apparent increases in tissue density. The resulting “ineffective repair” in ONFH may therefore reflect dysfunction across an interconnected cellular network. Restoration of macrovascular perfusion alone may be insufficient when the microvascular and immunometabolic environment remains compromised. This bone-vascular-immune framework should be regarded as an evidence-stratified model that integrates ONFH-specific observations with mechanistic evidence derived from related musculoskeletal and sterile inflammatory diseases. Among the candidate pathways discussed in this review, the SLC7A11/GPX4 ferroptosis axis currently has the strongest translational rationale because of its direct links to lipid peroxidation, oxidative injury, and structural repair failure in ONFH-relevant models. The NLRP3/caspase-1/GSDMD pyroptosis axis represents a second priority for limiting inflammatory amplification and IL-1β/IL-18-mediated osteovascular injury, although macrophage-specific validation remains necessary. HIF-1α-associated glycolytic reprogramming should be considered a potential upstream regulator of macrophage maladaptation and vascular–osteogenic uncoupling. However, its therapeutic modulation must be carefully balanced against the physiological role of hypoxia-induced angiogenesis. These targets should therefore undergo staged validation in ONFH-specific models before clinical translation is considered. Therapeutic development has increasingly focused on dynamic modulation of the lesion microenvironment, supported by advances in experimental delivery systems and biomaterial design. Engineered extracellular vesicle-based systems, stimuli-responsive nanocarriers, and nucleic acid-based tools should currently be regarded as experimental or preclinical platforms for evaluating target engagement and local delivery in ONFH models rather than as clinically validated therapies. To achieve clinically meaningful repair, these platforms must address multiple biological requirements, including attenuation of the early inflammatory response, restoration of microvascular integrity, and support of osteogenic differentiation. The deep anatomical location, poor microvascular accessibility, and cortical bone barrier of the femoral head impose additional demands for spatially precise delivery to defined tissue compartments and cell populations. Approaches such as metabolic glycoengineering, enhanced endosomal escape, and organelle-directed targeting of mitochondria or lysosomes may improve subcellular delivery precision. Programmable and microenvironment-responsive materials may also provide useful design principles for staged local intervention, although their application to ONFH remains largely conceptual. Future studies should first establish whether simpler, locally retained delivery systems can achieve reproducible target engagement and functional repair before progressing to more complex programmable platforms. The clinical translation of these experimental strategies faces three interrelated challenges: limited fidelity of preclinical models, insufficient long-term safety assessment, and difficulties in achieving reproducible large-scale manufacturing. Although rodent models are experimentally convenient, they do not adequately reproduce the biomechanical loading conditions or immune architecture of human ONFH. Greater emphasis should therefore be placed on microphysiological systems and large-animal models with skeletal and immunological characteristics that more closely approximate those of humans. Safety evaluation must extend beyond short-term biocompatibility to encompass the long-term effects of sustained immunomodulation on immune homeostasis, including impaired tumor immune surveillance and increased susceptibility to opportunistic infection. Given the inherent complexity of extracellular vesicle-based products, rigorous chemistry, manufacturing, and controls frameworks are required. Traceable critical quality attributes, including particle-size distribution, surface-marker consistency, and functional potency, must be established to provide the evidence necessary for regulatory evaluation and clinical development. Biomarker-guided stratification may eventually enable more individualized treatment selection, but this approach remains investigational in ONFH. Candidate imaging, serum, vascular, and immunometabolic biomarkers should be prospectively validated before being used to guide clinical trial design or therapeutic decision-making. Integrating spatial transcriptomics, radiomics, and peripheral blood immune biomarkers may facilitate the rational design of combination regimens tailored to individual pathogenic drivers and comorbid vulnerabilities. Candidate intermediate endpoints, including circulating biomarkers of endothelial subtypes and serum- or MRI-derived iron indices, likewise require prospective validation as surrogate measures of clinical efficacy before incorporation into trial design. Reframing ONFH as a potential localized manifestation of systemic immunometabolic dysregulation may ultimately shift therapeutic attention toward the prenecrotic window, before progressive structural damage becomes increasingly resistant to intervention. Exploiting this window will require validated biomarkers capable of identifying at-risk individuals before detectable necrotic changes occur. Addressing this unmet need will require prospective cohort studies in high-risk populations, including patients receiving GCs. Defining the spatial and temporal organization of pathological cellular networks during this period will be necessary to move the field from empirically guided, mechanically focused interventions toward mechanistically informed precision-regenerative strategies. Although advances in joint-preserving surgery have improved outcomes in selected patient populations, a unified mechanistic framework capable of predicting and sustaining durable biological repair has yet to be established. Author contributions JianXiong Ma: Conceptualization, Supervision, Project administration, Funding acquisition, Writing – review & editing. Yan Wang: Conceptualization, Resources, Visualization, Writing – review & editing. LuLu Zhang: Conceptualization, Methodology, Investigation, Writing – original draft, Visualization. XueZhi Liu: Conceptualization, Methodology, Investigation, Writing – original draft, Visualization. Dong Wang: Resources, Validation, Writing – review & editing. All authors have read and agreed to the published version of the manuscript. Declaration of generative AI and AI-assisted technologies in the writing process During the preparation of this manuscript, the authors used AI-assisted tools solely for language editing (grammar, clarity, and readability). The authors reviewed and verified all content, including scientific statements and citations, and take full responsibility for the manuscript. No generative AI or AI-assisted image-generation tools were used to create the figures or graphical abstract. All figures and the graphical abstract were manually prepared by the authors using BioGDP, BioRender, and Adobe Illustrator based on the mechanistic framework developed in this review. Declaration of competing interests The authors declare no competing interests. Funding Research in the authors' laboratory is supported by National Natural Science Foundation of China (NSFC) grants (82405109), Tianjin Education Commission Scientific Research Program (2024ZXZD001) and Tianjin Science and Technology Program Project (25JCZDJC01350). Footnotes Supplementary data to this article can be found online at https://doi.org/10.1016/j.jot.2026.101212. Supplementary data The following is the Supplementary data to this article: Multimedia component 1 References Associated Data Supplementary Materials Multimedia component 1